Despite advances in prostate cancer diagnosis and management, morbidity from prostate
cancer remains high. Approximately 20% of men present with advanced or metastatic …

CONTEXT: MicroRNAs (miRNA) are noncoding RNAs that post-transcriptionally regulate
gene expression. Their altered expression and function have been observed in most …

Context Various molecular mechanisms play a role in the development of resistance to
androgen deprivation therapy in castration-resistant prostate cancer (CRPC). Objective To …

Background Enzalutamide is an oral androgen-receptor inhibitor that prolongs survival in
men with metastatic castration-resistant prostate cancer in whom the disease has …

While mutations affecting protein-coding regions have been examined across many
cancers, structural variants at the genome-wide level are still poorly defined. Through …

Although recent studies have indicated roles of long non-coding RNAs (lncRNAs) in
physiological aspects of cell-type determination and tissue homeostasis, their potential …

Purpose The prevalence and features of treatment-emergent small-cell neuroendocrine
prostate cancer (t-SCNC) are not well characterized in the era of modern androgen receptor …

Background In advanced prostate cancer (APC), successful drug development as well as
advances in imaging and molecular characterisation have resulted in multiple areas where …

Although prostate cancer (CaP) is the most frequently diagnosed malignant tumor and the
second leading cause of cancer deaths in American men, the mechanisms explaining the …

Enzalutamide significantly improved radiographic progression-free survival (rPFS) and
overall survival (OS) among men with chemotherapy-naïve metastatic castration-resistant …